About Precision Biologics
Precision Biologics is a Healthcare company based in Dallas (United States) founded in 2012, and was acquired by NantWorks in October 2015. Precision Biologics is focused on developing innovative cancer therapies. It operates on a HealthTech model. Precision Biologics has raised $14.58 million across 3 funding rounds from investors including NantWorks. The company has 4 employees. Precision Biologics has completed 1 acquisition, including Neogenix Oncology. Precision Biologics offers products and services including Anticancer Vaccines, Monoclonal Antibodies, and Antibody-Drug Conjugate PB-223 ADC. Its focus areas include Biotechnology and Cancer Therapeutics. Its legal entity is Precision Biologics, Inc. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
Precision Biologics is engaged in the development of innovative therapeutic and diagnostic products for cancer patients. The company operates in the biotechnology sector, specializing in cancer therapeutics. Its solutions include patient tumor-derived anticancer vaccines, targeted monoclonal antibodies, and antibody-drug conjugates like PB-223 ADC. These products are designed to address unmet needs in cancer treatment by targeting tumors without harming healthy cells. Research and development efforts are supported by a unique discovery platform and breakthroughs in biotechnology.
- Headquarters Dallas, United States
- Employees 4
- Stage Acquired
- SectorsHealthcare
- Phone•••• ••••
- Website precision-biologics.com
- Social LinkedIn
- Acquired by NantWorks (Oct 2015)
- Legal Name Precision Biologics, Inc.
- Total Equity Funding$14.58M (USD)
in 3 rounds
- Latest Funding Round$795K (USD), Series A
Apr 2014
- Investors
- Employee Count4
- Investments & Acquisitions
- Acquired byNantWorks
(Oct 2015)
Products & Services of Precision Biologics
Precision Biologics offers a comprehensive portfolio of products and services, including Anticancer Vaccines, Monoclonal Antibodies, and Antibody-Drug Conjugate PB-223 ADC.
Patient tumor-derived vaccines are developed for cancer treatment.
Targeted antibodies are designed for tumor-specific cancer therapy.
Innovative conjugate is created for targeted cancer drug delivery.
Funding Insights of Precision Biologics
Precision Biologics has successfully raised a total of $14.58M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $795 thousand completed in April 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $14.58M
- Total Rounds 3
- Last Round Series A — $795,000
- First Round $3.29M
(May 2013)
All 3 funding rounds of Precision Biologics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2014 | $795,000 | Series A | – | – | – |
| Dec 2013 | $10.5M | Series A | – | – | – |
| May 2013 | $3.29M | Series A | – | – | – |
1 investors in total: 1 institutional.
Investors in Precision Biologics
Precision Biologics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include NantWorks.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Network of technology and infrastructure companies focused on healthcare development | 2006 | nantworks.com | Culver City, United States |
Investor details for Precision Biologics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Precision Biologics
4 people are tracked at Precision Biologics (4 in leadership); the tracked headcount is 4.
| Name | Role | Group |
|---|---|---|
Sharon A. Mavroukakis | Head Clinical & Regulatory | Leadership |
Al Tsang | Chief Scientific Officer | Leadership |
Philip Arlen | President & CEO | Leadership |
Massimo Fantini | Director Research & Development | Leadership |
Complete people profiles for Precision Biologics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Precision Biologics
Precision Biologics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Neogenix Oncology.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Therapeutic and diagnostic antibodies are developed for cancer treatments. | neogenixoncology.com | Great Neck, United States | 2003 | Jul 2012 | •••• |
Complete acquisition details for Precision Biologics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Precision Biologics
5 dated milestones of Precision Biologics across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Precision Biologics is founded.
- Acquisition Acquires Neogenix Oncology.
- Funding First funding round of $3.3M.
- Funding Latest funding round, Series A, of $795K.
- Exit Acquired by NantWorks.
Competitors of Precision Biologics
Precision Biologics has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of Precision Biologics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Precision Biologics
The website of Precision Biologics (precision-biologics.com) receives about 1.8K visits a month.
- Monthly visits1.8K
▲ 31.3% vs previous month
Websites whose visitors overlap most with Precision Biologics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| google.com | 100% | 85.8B | #1 | View details |
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Precision Biologics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Precision Biologics
Complete news archive for Precision Biologics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Precision Biologics
Precision Biologics was founded in 2012 and raised its 1st funding round 1 year after it was founded.
Precision Biologics is headquartered in Dallas, United States. It is registered at Dallas, Texas, United States.
Precision Biologics is a funded company, having raised a total of $14.58M across 3 funding rounds to date. The company's 1st funding round was a Series A of $3.29M, raised on May 2013.
Precision Biologics has 4 employees.
Precision Biologics is engaged in the development of innovative therapeutic and diagnostic products for cancer patients. The company operates in the biotechnology sector, specializing in cancer therapeutics. Its solutions include patient tumor-derived anticancer vaccines, targeted monoclonal antibodies, and antibody-drug conjugates like PB-223 ADC. These products are designed to address unmet needs in cancer treatment by targeting tumors without harming healthy cells. Research and development efforts are supported by a unique discovery platform and breakthroughs in biotechnology.
Precision Biologics offers Anticancer Vaccines, Monoclonal Antibodies, and Antibody-Drug Conjugate PB-223 ADC.
Precision Biologics has made 1 acquisition, including Neogenix Oncology.
Precision Biologics has 1 investor. Key investors include NantWorks.
Precision Biologics operates through Precision Biologics, Inc..
Yes. Precision Biologics was acquired by NantWorks in October 2015.